In patients with aspirin exacerbated respiratory disease, treatment with omalizumab resulted in "clinically silent" aspirin desensitization.
Budesonide-formoterol as needed was not inferior compared with budesonide maintenance therapy in terms of severe asthma exacerbation rates, but may be inferior for controlling symptoms.
There was a 60% lower rate of severe asthma exacerbations in individuals treated with budesonide-formoterol compared with individuals treated with terbutaline as needed.
Early clinical response rates were similar across PORT risk class subgroups in patients with community-acquired bacterial pneumonia when treated with omadacycline or moxifloxacin.
PCV13, marketed as Prevnar 13, was evaluated in a test-negative case-control study in real-world conditions where patients were administered pneumococcal vaccination as advised by their healthcare providers.
In patients with acute respiratory failure, high-flow nasal cannula and conventional oxygen therapy provided similar benefits.
In the LEAP 2 study (N=738), patients with moderate CABP received either oral lefamulin 600mg every 12 hours for 5 days or oral moxifloxacin 400mg once daily for 7 days.
Liberal supplemental oxygen therapy in acutely ill patients increased mortality during hospitalization, at 30 days, and at longest follow-up.
Tiotropium may be more effective in reducing the rate of moderate and severe chronic obstructive pulmonary disorder exacerbations when used in combination with olodaterol vs tiotropium alone.
Researchers evaluated barrier dysfunction by exposing viral models to budesonide, montelukast, formoterol, or a combination.
Inhaled interferon-beta 1 a did not significantly reduce acute asthma exacerbations during respiratory viral infections.
In this study, researchers examined the appropriateness of diagnosis and treatment of chronic obstructive pulmonary disease in individuals with and without HIV.
Steroid dosing and glucose levels were not associated with an increase in hospital readmissions related to COPD exacerbations.
Inhaled corticosteroids for asthma dosed once daily in the evening appeared to offer some benefit in trough FEV1 and morning peak expiratory flow.
The pooled safety analysis included data from the TRILOGY, TRINITY, and TRIBUTE studies.
Incident diuretic use was associated with increased rates of respiratory-related morbidity and mortality in older adults with chronic obstructive pulmonary disease.
Subcutaneous dupilumab significantly reduced the use of oral corticosteroids in patients with corticosteroid-dependent severe asthma.
Peak expiratory flow increases were greater with benralizumab than placebo in patients with severe eosinophilic asthma.
In individuals with asthma and vitamin D deficiency, vitamin D supplementation improved asthma control.
Combination therapy with LABA and LAMA yielded a lower annualized rate of COPD exacerbations compared with triple therapy.
While macrolides had no direct effect on lung function, their use significantly improved asthma control and quality of life in patients with asthma.
Fixed continuous positive airway pressure for the treatment of obstructive sleep apnea was associated with preventing a time-dependent decline in estimated glomerular filtration rate.
Nasal beclomethasone dipropionate was more effective in improving nasal patency and cytology as well as quality of life compared with cetirizine in children with perennial allergic rhinitis.
The initiative helped reduce the ordering of chest radiographs, respiratory viral testing, and bronchodilators.
The study authors reported, "The most commonly reported problems by youth were: (a) hard to remember when to take the asthma medication (54%) and (b) hard to use asthma medication at school (34%)."
At the end of 6 months, the rate of VTE recurrence was 4% among rivaroxaban patients vs 11% in the dalteparin arm (hazard ratio [HR] 0.43, 95% CI: 0.19 to 0.99).
The study aimed to determine the association between ICS therapy adherence and the occurrence of asthma exacerbations in patients with high blood eosinophil levels.
Of the total 573 APFS dispensed, 1 malfunctioned and 1 was considered nonfunctional because it was not returned. The study authors also reported that patient-use error only led to 2 unsuccessful at-home administrations.
Copeptin may be useful for identifying normotensive patients with pulmonary embolism who have a higher risk for an adverse outcome.
PHQ-9 and PHQ-2 show factorial validity, invariance, and reliability for measuring depression in patients with chronic obstructive pulmonary disease.